Dr. Rinn Song joined OVG and the Department of Paediatrics in September 2017 as a Clinician-Scientist and Honorary Consultant in Paediatric Infectious Diseases. Dr. Song completed his medical studies at the Ludwig-Maximilians-University in Munich, Germany, with an MD and a Doctorate Degree in Medicine (MD Res) with a focus on Health Services Research. He completed his clinical training in Paediatrics at New York University in New York, USA, followed by training in Applied Epidemiology and Public Health as an Epidemic Intelligence Service Officer in the TB Division of the US Centers for Disease Control and Prevention. Up until joining the University of Oxford, he has been an affiliated Scientist with the TB Division of the CDC.
He completed his training in Paediatric Infectious Diseases at Boston Children’s Hospital/Harvard Medical School and then joined the faculty of the Department of Paediatrics of Harvard Medical School in 2012. He has been a Consultant in Paediatric Infectious Diseases at Boston Children’s Hospital since 2012 and is board certified in Paediatrics and Paediatric Infectious Diseases by the American Board of Pediatrics. He holds an MPH from the Harvard School of Public Health and an MSc in Immunology of Infectious Diseases from the London School of Hygiene and Tropical Medicine. Prior to joining OVG, he has also been working with FIND, Switzerland, on the development and evaluation of novel TB diagnostics.
Dr. Song's primary research area is paediatric TB, with a specific interest in paediatric TB diagnostics. Dr. Song is involved in a number of US NIH-funded global studies in this area, including the FEND TB consortium (https://www.fend-tb.org) where he leads the paediatric component, and the NOD TB and PREDICT TB studies in Uganda and in Peru, among others.
Dr. Song served also as the Principal Investigator for safety of all national and international studies of the Oxford-Astrazeneca COVID-19 vaccine and he was the Oxford Principal Investigator for the paediatric vaccine trial. He is the Chief Investigator for the "6-in-1 part 2" study.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M. et al, (2021), Lancet, 397, 881 - 891
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Barrett JR. et al, (2021), Nat Med, 27, 279 - 288
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Ewer KJ. et al, (2021), Nat Med, 27, 270 - 278
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Voysey M. et al, (2021), Lancet, 397, 99 - 111